SUBSCRIBE
SUBSCRIBE

Organon

NEWS
Biotech Beach
The Day In Review: Schering-Plough Corporation Buys Organon For $14.4 Billion
March 12, 2007
 · 
1 min read
BioForest
National Institutes of Health (NIH) Awards Nearly $11.5 Million To Support Science Education Programs
January 4, 2007
 · 
1 min read
Biotech Beach
The Day In Review: ImClone Systems Incorporated Loses Erbitux Patent Fight
September 19, 2006
 · 
1 min read
Load More
JOBS
IN THE PRESS
Press Releases
FDA Approves VTAMA® (tapinarof) cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older
December 16, 2024
 · 
9 min read
Press Releases
Update on FDA Review of VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older
November 6, 2024
 · 
6 min read
Press Releases
Organon Reports Results for the Third Quarter Ended September 30, 2024
October 31, 2024
 · 
19 min read
US FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab)
October 30, 2024
 · 
5 min read
Press Releases
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
October 28, 2024
 · 
11 min read
Press Releases
Organon to Report Third Quarter 2024 Results and Host Conference Call on October 31, 2024
October 9, 2024
 · 
3 min read
Press Releases
Primary Endpoint Met in Phase 3 Comparative Clinical Study of Perjeta® (pertuzumab) Biosimilar Candidate HLX11
September 30, 2024
 · 
5 min read
Business
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
September 18, 2024
 · 
16 min read
Press Releases
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
September 18, 2024
 · 
16 min read
Pharm Country
European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14
May 24, 2024
 · 
7 min read
Load More